- Home
- ALX vs IMNM Comparison
ALX vs IMNM Comparison
Compare ALX & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALX
- IMNM
- Stock Information
- Founded
- ALX 1928
- IMNM 2006
- Country
- ALX United States
- IMNM United States
- Employees
- ALX N/A
- IMNM N/A
- Industry
- ALX Real Estate Investment Trusts
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- ALX Real Estate
- IMNM Health Care
- Exchange
- ALX Nasdaq
- IMNM Nasdaq
- Market Cap
- ALX 1.2B
- IMNM 1.2B
- IPO Year
- ALX N/A
- IMNM 2020
- Fundamental
- Price
- ALX $220.93
- IMNM $16.07
- Analyst Decision
- ALX
- IMNM Strong Buy
- Analyst Count
- ALX 0
- IMNM 9
- Target Price
- ALX N/A
- IMNM $24.89
- AVG Volume (30 Days)
- ALX 76.8K
- IMNM 1.3M
- Earning Date
- ALX 11-03-2025
- IMNM 11-14-2025
- Dividend Yield
- ALX 8.15%
- IMNM N/A
- EPS Growth
- ALX N/A
- IMNM N/A
- EPS
- ALX 7.28
- IMNM N/A
- Revenue
- ALX $218,089,000.00
- IMNM $12,589,000.00
- Revenue This Year
- ALX N/A
- IMNM N/A
- Revenue Next Year
- ALX N/A
- IMNM $85.68
- P/E Ratio
- ALX $30.35
- IMNM N/A
- Revenue Growth
- ALX N/A
- IMNM 16.74
- 52 Week Low
- ALX $184.76
- IMNM $5.15
- 52 Week High
- ALX $260.84
- IMNM $17.32
- Technical
- Relative Strength Index (RSI)
- ALX 38.15
- IMNM 61.62
- Support Level
- ALX $228.45
- IMNM $15.44
- Resistance Level
- ALX $238.16
- IMNM $17.21
- Average True Range (ATR)
- ALX 6.93
- IMNM 1.13
- MACD
- ALX -1.70
- IMNM -0.15
- Stochastic Oscillator
- ALX 23.01
- IMNM 67.04
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.